Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427493 | 0.86 | PIK3CD (0.41) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL12436 | 0.86 | PIK3CD (0.41) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL13981437 | 0.85 | CYP2D6 (0.44) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL772434 | 0.85 | PIK3CD (0.40) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL24997025 | 0.85 | CYP2D6 (0.44) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL23374535 | 0.83 | PIK3CD (0.39) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL18844599 | 0.82 | CHRM5 (0.42) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL21506203 | 0.80 | KDM4E (0.37) | PIK3CDCHRM5ADRA2CKDM4EPOLB | |
| SCHEMBL12000484 | 0.78 | KDM4E (0.61) | PIK3CDKDM4EPOLBKMT2AALDH1A1 | |
| SCHEMBL12449688 | 0.78 | KDM4E (0.61) | PIK3CDKDM4EPOLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | PIK3CD 1771/4885CHRM5 3733/4885ADRA2C 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.